Osaka University and Chugai Pharmaceutical Co., Ltd. today announced the conclusion of a comprehensive collaboration agreement for advanced research in immunology between the Osaka University Immunology Frontier Research Center (IFReC) and Chugai.
Chugai will, according to the agreement, provide one billion yen per year for a period of 10 years, allowing IFReC to maintain an academic environment that allows researchers to focus on basic research originating from their own ideas, with the aim of contributing back to society the results of the advanced immunology research.
In addition, through the combination of the global top-class research in immunology at IFReC and the knowledge of innovative drug research accumulated by Chugai through its proprietary technologies, the obstacles between basic research and clinical application research will be eliminated. It is expected that this will lead to the unprecedented discovery of innovative novel drugs in the field of immunology.
(1) [Press Release] Comprehensive Collaboration Agreement between Osaka University and Chugai
(3) [From Chugai Pharmaceutical] Outline of Comprehensive Collaboration with IFReC